Zhang JQ, Duan Y, Wang K, Zhang XL, Jiang KH. Metachronous urothelial carcinoma in the renal pelvis, bladder, and urethra: A case report. World J Clin Cases 2023; 11(13): 3062-3069 [PMID: 37215428 DOI: 10.12998/wjcc.v11.i13.3062]
Corresponding Author of This Article
Ke-Hua Jiang, MD, Professor, Department of Urology, Guizhou Provincial People’s Hospital, No. 52 Zhongshan East Road, Nanming District, Guiyang 550002, Guizhou Province, China. tjjkh@sina.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 6, 2023; 11(13): 3062-3069 Published online May 6, 2023. doi: 10.12998/wjcc.v11.i13.3062
Metachronous urothelial carcinoma in the renal pelvis, bladder, and urethra: A case report
Jian-Qing Zhang, Yu Duan, Kun Wang, Xiao-Li Zhang, Ke-Hua Jiang
Jian-Qing Zhang, Yu Duan, Kun Wang, Ke-Hua Jiang, Department of Urology, Guizhou Provincial People’s Hospital, Guiyang 550002, Guizhou Province, China
Xiao-Li Zhang, Department of Biomedicine, Guizhou University, Guiyang 550025, Guizhou Province, China
Author contributions: Zhang JQ, Duan Y and Wang K contributed to this work; Jiang KH designed the study; Zhang JQ and Duan Y drafted the manuscript; Wang K and Zhang XL collected the clinical data; All authors have read and approved the final manuscript.
Supported byNational Natural Science Foundation of China, No. 82060462; The Science and Technology Plan Project of Guizhou Province, No. [2019]5405; Foundation of Health and Family Planning Commission of Guizhou Province, No. gzwjkj2019-1-127
Informed consent statement: Written informed consent was obtained from the patient for the publication of this case report.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ke-Hua Jiang, MD, Professor, Department of Urology, Guizhou Provincial People’s Hospital, No. 52 Zhongshan East Road, Nanming District, Guiyang 550002, Guizhou Province, China. tjjkh@sina.com
Received: November 28, 2022 Peer-review started: November 28, 2022 First decision: December 19, 2022 Revised: February 6, 2023 Accepted: March 31, 2023 Article in press: March 31, 2023 Published online: May 6, 2023 Processing time: 148 Days and 2.2 Hours
Core Tip
Core Tip: Urothelial carcinoma (UC) is a common malignancy in the urinary system, and typically grows from multiple foci. UC is most common in the bladder, and upper urinary tract UC (UTUC) is rare. We describe a male who initially presented at a local hospital in 2015 at the age of 70 years with a complaint of painless hematuria. The doctors diagnosed UTUC of the right renal pelvis. After radical nephroureterectomy and bladder cuff excision, the doctors recommended intravesical chemotherapy and regular follow-up, but he rejected this advice. He presented at our hospital again with dysuria in 2016. We identified UC in the residual bladder and performed radical cystectomy and left cutaneous ureterostomy. Unfortunately, he presented again with urethral orifice bleeding in 2021, and we identified urethral UC as the cause. We thus administered radical urethrectomy. Since this last surgery, he has received regular 6-mo follow-ups and has remained in a stable condition. Treatment for upper UTUC should include adjuvant instillation as immunotherapy and intense surveillance.
